Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$37.89

6.63 (21.21%)

07:54
01/11/17
01/11
07:54
01/11/17
07:54

Sarepta EXONDYS 51 launch encouraging, says RBC Capital

RBC Capital analyst Simos Simeonidis notes that Sarepta reported that it only obtained revenue of $5.4M from its EXONDYS 51 in the wake of its launch. However, the analyst is "encouraged by the disclosure that 250 forms have been filled out for patients whose mutation status has been verified" as of the end of last year. Simeonidis continues to predict that the drug will undergo a "slow and gradual ramp," with its sales accelerating significantly in the "later" quarters of this year. The analyst keeps a $98 price target and an Outperform rating on the stock.

SRPT Sarepta
$37.89

6.63 (21.21%)

01/06/17
JMPS
01/06/17
NO CHANGE
Target $65
JMPS
Outperform
Sarepta price target lowered to $65 after physician survey at JMP Securities
JMP Securities analyst Liisa Bayko reported the firm conducted its first survey of U.S. physicians who treat Duchenne muscular dystrophy patients to gauge early experiences with Sarepta's Exondys 51. At the end of 2016, respondents had written a prescription to about 1 in 5 eligible patients, 1 in 5 were denied coverage and about 15% were in the adjudication process, noted Bayko, who lowered her price target on Sarepta to $65 from $90 to adjust for the survey results as well as an updated pricing analysis. Bayko keeps an Outperform rating on Sarepta and said she sees potential upside to about $160 per share if Exondys 51 is approved in the EU and if all of its earlier-stage assets targeting exons 45/53 are successful.
01/10/17
BARD
01/10/17
NO CHANGE
Target $102
BARD
Outperform
Baird expects Sarepta 'relief rally' on launch update
Baird analyst Brian Skorney expects a "relief rally" in shares of Sarepta Therapeutics after the company announced Exondys 51 sales of $5.4M and greater than 250 patient start forms were submitted by year-end. If the shares were at $60, the sales figure would be a disappointment, but expectations have been lowered and whisper numbers were nearing negative territory, Skorney tells investors in a research note following Sarepta's JPMorgan Conference presentation. "This is just the beginning," as the company has dystrophin data coming from SRP-4053 in exon-53-amenable patients in the first half of 2017 and data plans to advance at least three additional assets, the analyst contends. Skorney keeps an Outperform rating on Sarepta with a $102 price target.
01/10/17
LEER
01/10/17
NO CHANGE
LEER
Market Perform
Leerink discusses discrepancy between Sarepta revenue, start forms
Leerink analyst Joseph Schwartz says that for Sarepta Therapeutics to meet the Q4 revenue estimate of $6.0M, he anticipated a greater than 200 start form number. The company, however, reported $5.4M in sales despite a start form number of over 250. The discrepancy between start forms and the revenue miss could be due to several factors, including the translatability of start forms to reimbursed written prescriptions and patient demographics, Schwartz tells investors in a research note. Continued push-back from payors that limit reimbursement could render the start form number inaccurate, he contends. The analyst views today's numbers from Sarepta as "encouraging," but sees room for improvement. Schwartz keeps a Market Perform rating on the shares.
01/10/17
PIPR
01/10/17
NO CHANGE
Target $68
PIPR
Overweight
Piper says Sarepta Q4 sales topped estimate
Piper Jaffray analyst Edward Tenthoff says Sarepta Therapeutics' Q4 Exondys 51 sales of $5.4M beat his estimate of $4.5M. The company is making good progress on reimbursement and expects payor conversions to accelerate in Q2, Tenthoff tells investors in a research note. He estimates U.S. Exondys 51 sales of $274M in 2017 with peak U.S. sales of greater than $500M. Tenthoff reiterates an Overweight rating on Sarepta with a $68 price target.

TODAY'S FREE FLY STORIES

FLR

Fluor

$44.29

0.52 (1.19%)

12:20
06/22/17
06/22
12:20
06/22/17
12:20
Options
Flour calls seeing opening interest »

Flour calls seeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:17
06/22/17
06/22
12:17
06/22/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
06/22/17
06/22
12:16
06/22/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSIQ

Canadian Solar

$13.99

0.94 (7.20%)

12:10
06/22/17
06/22
12:10
06/22/17
12:10
Options
Notable call buying in Canadian Solar as shares shine »

Notable call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:10
06/22/17
06/22
12:10
06/22/17
12:10
General news
Treasury Option Action: a call 1x2 on 10s »

Treasury Option Action: a…

SRSC

Sears Canada

$0.47

-0.115 (-19.69%)

12:05
06/22/17
06/22
12:05
06/22/17
12:05
Hot Stocks
Breaking Hot Stocks news story on Sears Canada »

Sears Canada trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLSN

Nielsen

$37.08

-0.15 (-0.40%)

, GOOG

Alphabet

$959.45

8.82 (0.93%)

12:01
06/22/17
06/22
12:01
06/22/17
12:01
Hot Stocks
Nielsen launches mobile measurement for YouTube ads »

Nielsen (NLSN) announced…

NLSN

Nielsen

$37.08

-0.15 (-0.40%)

GOOG

Alphabet

$959.45

8.82 (0.93%)

GOOGL

Alphabet Class A

$978.59

9.6 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

AKS

AK Steel

$6.25

0.055 (0.89%)

12:00
06/22/17
06/22
12:00
06/22/17
12:00
Options
AK Steel Jul 8 calls are today's most active option »

AK Steel Jul 8 calls are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

CVM

CEL-SCI

$1.75

0.0576 (3.41%)

11:58
06/22/17
06/22
11:58
06/22/17
11:58
Hot Stocks
Breaking Hot Stocks news story on CEL-SCI 

Cel Sci trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$33.16

0.13 (0.39%)

11:55
06/22/17
06/22
11:55
06/22/17
11:55
Hot Stocks
Hain Celestial CEO says he has a strong management team backing him »

The Hain Celestial CEO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 27

    Jun

HAIN

Hain Celestial

$33.16

0.13 (0.39%)

, AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

11:53
06/22/17
06/22
11:53
06/22/17
11:53
Hot Stocks
Hain Celestial says Amazon deal for Whole Foods will give more exposure »

The Hain Celestial CEO is…

HAIN

Hain Celestial

$33.16

0.13 (0.39%)

AMZN

Amazon.com

$1,002.23

9.64 (0.97%)

WFM

Whole Foods

$43.26

0.48 (1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 27

    Jun

  • 28

    Jun

SPLS

Staples

$8.66

-0.09 (-1.03%)

11:47
06/22/17
06/22
11:47
06/22/17
11:47
Recommendations
Staples analyst commentary  »

Staples intrinsic value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMSI

Merit Medical

$36.80

-0.2 (-0.54%)

11:46
06/22/17
06/22
11:46
06/22/17
11:46
Recommendations
Merit Medical analyst commentary  »

Merit Medical allowance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

FSLR

First Solar

$37.23

1.78 (5.02%)

11:45
06/22/17
06/22
11:45
06/22/17
11:45
Options
First Solar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

ABBV

AbbVie

$72.80

1.455 (2.04%)

11:44
06/22/17
06/22
11:44
06/22/17
11:44
Upgrade
AbbVie rating change  »

AbbVie upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMC

Commercial Metals

$18.47

0.06 (0.33%)

11:38
06/22/17
06/22
11:38
06/22/17
11:38
Hot Stocks
Breaking Hot Stocks news story on Commercial Metals »

Commercial Metals says a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

LPNT

LifePoint

$64.85

0.25 (0.39%)

, CYH

Community Health

$9.56

0.74 (8.39%)

11:35
06/22/17
06/22
11:35
06/22/17
11:35
Hot Stocks
Hosptial stocks at highs after Republicans release ACHA 'discussion draft' »

Publicly traded companies…

LPNT

LifePoint

$64.85

0.25 (0.39%)

CYH

Community Health

$9.56

0.74 (8.39%)

THC

Tenet

$18.94

1.26 (7.13%)

HCA

HCA Holdings

$87.44

3.39 (4.03%)

UHS

Universal Health

$116.28

3.06 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$38.27

0.85 (2.27%)

11:26
06/22/17
06/22
11:26
06/22/17
11:26
Periodicals
Mylan investors vote against executive pay, re-elect board members, Reuters says »

Mylan shareholders voted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 13

    Jul

  • 03

    Sep

  • 09

    Oct

11:25
06/22/17
06/22
11:25
06/22/17
11:25
General news
Treasury announced an $88 B package of coupon offerings for next week »

Treasury announced an $88…

V

Visa

$94.25

-0.29 (-0.31%)

11:23
06/22/17
06/22
11:23
06/22/17
11:23
Hot Stocks
Breaking Hot Stocks news story on Visa »

Visa says 'engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

KR

Kroger

$22.12

-0.2542 (-1.14%)

11:21
06/22/17
06/22
11:21
06/22/17
11:21
Hot Stocks
Kroger board approves $1B share repurchase program, raises quarterly dividend »

The Kroger Co.'s…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

V

Visa

$94.21

-0.33 (-0.35%)

11:20
06/22/17
06/22
11:20
06/22/17
11:20
Hot Stocks
Visa says continues to pursue domestic license in China »

Says regulation a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

BAC

Bank of America

$23.02

-0.115 (-0.50%)

11:20
06/22/17
06/22
11:20
06/22/17
11:20
Options
Big block of BofA calls as shares dip »

Big block of BofA calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMC

Commercial Metals

$18.43

0.0192 (0.10%)

11:20
06/22/17
06/22
11:20
06/22/17
11:20
Hot Stocks
Commercial Metals says Q4 is usually a strong shipping quarter »

Sees Q4 margins stable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

$NSD

NASDAQ Market Internals

11:17
06/22/17
06/22
11:17
06/22/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.